InnoCare’s BTK inhibitor, orelabrutinib, has displayed promising efficacy during a Phase IIb trial in systemic lupus erythematosus (SLE), which will see the drug progress to a Phase III registrational ...
American beverage manufacture Anheuser-Busch has announced its acquisition of a majority stake in BeatBox, a rapidly growing player in the alcoholic ready-to-drink (RTD) beverage sector. This deal ...
Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025, enhancing treatment options. Managed Healthcare Executive spoke with Jeff ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Austin-based BeatBox is set to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback